INNOVATIONS in pharmacy
The purpose of this commentary is to (1) review the definition and potential benefits of translational science research, (2) comment on funding trends for translational science, (3) pose a question for scientists to discuss, and (4) propose recommendations for such a discussion.
Definition and Potential Benefits of Translational Science/Research
Translational science/research is a new and developing method for improving human health. The meaning of the method is translating scientific discoveries into practical applications. In the beginning, discoveries started at "the bench" with basic research -in which scientists study disease at a molecular or cellular level -then progress to the clinical level, or the patient's "bedside".
This bench-to-bedside approach can be a two way method. 
Clinical and Translational Science Awards
To help foster the translational science approach, the National Institutes of Health (NIH) held the Clinical and Translational Science Awards (CTSA) Consortium in October 2006 for improving the new vision named translational science. 1 The purpose of the CTSA Program, which the National Center for Research Resources (NCRR) is leading on behalf of the NIH Roadmap for Medical Research (http://www.ncrr.nih.gov/), is to assist institutions to forge a uniquely transformative, novel, and integrative academic home for Clinical and Translational Science that has the consolidated resources to captivate, advance, and nurture a cadre of well-trained multi-and inter-disciplinary investigators and research teams; create an incubator for innovative research tools and information technologies; and synergize multi-disciplinary and inter-disciplinary clinical and translational research and researchers to catalyze the application of new knowledge and techniques to clinical practice at the front lines of patient care. 1 These efforts have resulted in many researchers who are using the translational method in their research. Also the research budgets of institutes are being allocated to translational research projects and this allocation is continuing to grow.
Cost-effectiveness of Translational Science/Research
In light of this new paradigm, we need to ask: "Are translational findings useful and cost-effective for patients and society?" If such an approach is not cost-effective, these budgets will be wasted. On the other hand, if this approach is cost-effective, it would be wise to allocate additional budget amounts into translational science research projects.
For example, if a biomarker for detecting kidney injury caused by diabetes or hypertension in an early phase could be identified, then treatment could be improved [2] [3] [4] [5] . However, the question becomes: "Is the bio-marker affordable enough so that it would be cost-effective to screen most diabetes or hypertension patients?"
In order to answer such a question, valid estimates related to prevalence and incidence of disease, treatment costs, screening costs, cost of illness, specificity of bio-markers, rates of inflation, and other factors must be developed. Such an approach would allow the consideration of potential costsavings through translational science.
Recommendations for Future Discussion
According to the U.S. Congressional Budget Office, there is "a limited amount of evidence available about which treatments 
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2 work best for which patients and whether the added benefits of more cost-effective but more-expensive services are sufficient to warrant their added costs. Together, those findings suggest that generating better information about the costs and benefits of different treatment options -through research on the comparative effectiveness of those optionscould help reduce health care spending without adversely affecting overall health." 6 We recommend that comparative effectiveness analysis should be integrated into translational science and research before, during, and after such "bench-to-bedside" research is conducted. We propose an enhanced approach that could be referred to as "bench-to-beside-to-best practices" research. This approach would incorporate basic, clinical, and costeffectiveness research in an iterative manner so that analysis could be conducted before budgets grow out of control.
We propose several questions and ideas for further discussion in this area: We present these ideas for further discussion. New ideas could be added and some ideas could be ignored. However, science and reality won`t wait. We need to talk about the cost-effectiveness of translational science and how the comparative effectiveness of new treatment modalities affect budgets.
